Canaccord Genuity Cuts BioNTech (BNTX) Price Target to $132

Canaccord Genuity has reiterated its Buy rating on BioNTech SE with a new price target of $132, a 49.12% upside from the current price.

By EarningsIQ Research Desk · Published Oct 16, 2026, 2:18 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Canaccord Genuity cut its price target on BioNTech SE ($BNTX) to $132 from $136 on October 14, 2026, and rates the stock "Buy".

Since the rating, $BNTX is down 1.1% to date (from the $88.66 close on Oct 14, 2026).

BNTX BioNTech SE

$87.71 -9.29% year to date

Daily close · Oct 16, 2026

Key Points

On October 14, 2026, Canaccord Genuity reiterated its Buy rating on BioNTech SE, setting a price target of $132, down from $136.
Canaccord Genuity's $132 price target implies 49.12% upside from BioNTech SE's ($BNTX) current $88.52 share price.
The stock trades recently around $88.52, which is about 32.9% below the new price target.
BioNTech has faced challenges with a significant year-over-year revenue decline of 59.5%, and its next earnings report is due on November 3, 2026.

Get $BNTX trade alerts by text

We text you when insiders, Congress or big funds trade $BNTX. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated BioNTech SE alert may contain errors. Disclosures

Canaccord Genuity reiterated its Buy rating on BioNTech SE (NasdaqGS: BNTX) on October 14, 2026. The firm set a new price target of $132, which is a decrease from the previous target of $136. This rating comes as the stock trades recently around $88.52, about 32.9% below the new target.

Other Institutional Activity in BioNTech

FMR, LLC holds 7,571,805 shares of BioNTech, having increased its position by 1,862,406 shares, worth approximately $664.1 million. Dodge & Cox Inc. has 3,677,591 shares, with a slight increase of 735 shares, valued at about $322.6 million. Primecap Management Company reduced its holdings by 21,624 shares, ending with 3,772,031 shares worth around $330.8 million. Meanwhile, both Flossbach von Storch SE and T. Rowe Price Investment Management, Inc. decreased their stakes significantly.

BioNTech SE Stock Down 1.9%

The stock is currently trading around $88.52, which is notably below its new price target of $132. This suggests that analysts see potential upside, despite the current price being lower than expected. The stock's performance will be closely watched, especially with the company facing a year-over-year revenue decline of 59.5%.

12-month forecast

$BNTX price target

BioNTech SE daily closes and this analyst's $132 target. Not advice.

Recent Earnings

For the trailing twelve months, BioNTech reported revenue of approximately $2.65 billion, but it has faced a net margin of -63.6%. Its next earnings report is scheduled for November 3, 2026, which could provide further insights into its financial health.

Insider Buying and Selling at BioNTech SE

Chief Executive Officer Ugur Md Sahin has been active in selling shares. On October 7, 2026, he sold 24,000 shares at an average price of $95.86, totaling about $2.3 million. Earlier, he sold 93,000 shares on October 6, 2026, for approximately $9.0 million. These sales occurred before the recent analyst ratings and could indicate personal financial strategies rather than company outlook.

Analysts Set New Price Targets

On October 14, 2026, Canaccord Genuity maintained its Buy rating on BioNTech with a price target of $132, down from $136. This follows a series of rating adjustments from other firms, with Citigroup maintaining a Buy rating and a target of $125, and BMO Capital downgrading to Market Perform with a target of $105.

About BioNTech

BioNTech SE, based in Mainz, Germany, focuses on developing and commercializing immunotherapies, particularly mRNA vaccines, including those for the SARS-CoV-2 virus. The firm's innovative approach has placed it at the forefront of biopharmaceutical development, making its stock a point of interest for investors.

Bottom Line

Investors should watch BioNTech closely as it approaches its next earnings report on November 3, 2026. The company's recent performance and the adjustments in analyst ratings highlight the ongoing challenges it faces in the biotechnology sector.